Risk Stratification in Chronic Lymphocytic Leukemia
The Role of the Clinical Laboratory
Risk Assessment
November 2008
This slide highlights the three key points that a laboratory needs to be aware of in evaluating patients with CLL.
First, one needs to reach an accurate and correct diagnosis.
Second, in today’s environment, risk assessment is critical in order to help clinicians provide the appropriate therapy and follow-up for these patients.
Finally, there is the assessment of outcome and potentially the detection of minimal residual disease. As I mentioned previously, the diagnostic and outcome assessment were previously discussed, and today we will be focusing on risk assessment.
Risk Assessment |
Jump to section:
- Introduction
- Goals Today
- Risk Assessment
- Risk Assessment in CLL
- CLL Rai Stage: Treatment Free
- CLL: Nodular Pattern of BM Infiltration
- CLL: Pattern of BM Infiltration
- Blood: Prognostic Indicators
- CLL and Fragile Cells
- CLL: Fragile Cells and Time to Treatment
- CLL Prognostics: CD38
- CLL Rai Stage 0: CD38
- ZAP-70 in B-CLL
- ZAP-70 in B-CLL: Detection
- ZAP-70 in B-CLL: Questions
- ZAP-70 by Flow in CLL
- ZAP-70 by Flow in CLL
- ZAP-70 by Flow in CLL
- ZAP-70: Immunohistochemistry
- CLL Rai Stage 0: ZAP-70
- CD49d in CLL
- CD49d: Clinical Role
- Time to Treatment (TTT) & Overall Survival (OS) from Diagnosis*
- CD49d in CLL
- CD49d in CLL
- Immunoglobulin Variable (IgVH) Region Mutation Status
- IgVH Sequencing
- CLL Rai Stage 0: IgVH
- Chromosome Anomalies in Chronic Lymphocytic Leukemia
- Distribution of Chromosome Anomalies in CLL Detected by FISH
- 13q-: A Microdeletion in B-CLL
- Overall Survival: By FISH Anomaly
- Risk Assessment in CLL: Summary
- Risk Assessment In CLL
- Risk Assessment
- Goals Today
- Questions?
External
link
PDF
document
Excel
document
Word
document